Compare Lupin Ltd with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs PROCTER & GAMBLE HEALTH - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN PROCTER & GAMBLE HEALTH LUPIN/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 48.6 51.5 94.4% View Chart
P/BV x 2.5 4.7 53.5% View Chart
Dividend Yield % 0.0 10.2 -  

Financials

 LUPIN   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    LUPIN
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
LUPIN/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs9863,549 27.8%   
Low Rs7201,301 55.4%   
Sales per share (Unadj.) Rs369.5511.4 72.2%  
Earnings per share (Unadj.) Rs13.461.3 21.9%  
Cash flow per share (Unadj.) Rs37.474.0 50.5%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs303.7927.8 32.7%  
Shares outstanding (eoy) m452.4916.60 2,725.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.34.7 48.7%   
Avg P/E ratio x63.639.6 160.9%  
P/CF ratio (eoy) x22.832.8 69.7%  
Price / Book Value ratio x2.82.6 107.5%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m386,06440,257 959.0%   
No. of employees `00017.71.1 1,559.4%   
Total wages/salary Rs m31,5131,313 2,400.6%   
Avg. sales/employee Rs Th9,453.87,486.7 126.3%   
Avg. wages/employee Rs Th1,782.01,157.6 153.9%   
Avg. net profit/employee Rs Th343.0897.2 38.2%   
INCOME DATA
Net Sales Rs m167,1828,490 1,969.2%  
Other income Rs m3,640244 1,492.5%   
Total revenues Rs m170,8228,734 1,955.9%   
Gross profit Rs m28,8221,482 1,945.3%  
Depreciation Rs m10,850211 5,137.4%   
Interest Rs m3,0780-   
Profit before tax Rs m18,5341,514 1,223.9%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,40066 -5,182.6%   
Tax Rs m9,017563 1,603.0%   
Profit after tax Rs m6,0661,017 596.2%  
Gross profit margin %17.217.5 98.8%  
Effective tax rate %48.737.1 131.0%   
Net profit margin %3.612.0 30.3%  
BALANCE SHEET DATA
Current assets Rs m138,53615,343 902.9%   
Current liabilities Rs m61,2991,960 3,127.2%   
Net working cap to sales %46.2157.6 29.3%  
Current ratio x2.37.8 28.9%  
Inventory Days Days8449 171.9%  
Debtors Days Days11228 395.2%  
Net fixed assets Rs m127,5161,209 10,544.6%   
Share capital Rs m905166 545.2%   
"Free" reserves Rs m136,51715,235 896.1%   
Net worth Rs m137,42215,401 892.3%   
Long term debt Rs m66,4170-   
Total assets Rs m279,49417,595 1,588.5%  
Interest coverage x7.0NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.5 124.0%   
Return on assets %3.35.8 56.6%  
Return on equity %4.46.6 66.8%  
Return on capital %8.910.3 86.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,4141,636 3,631.0%   
Fx outflow Rs m22,2824,368 510.1%   
Net fx Rs m37,132-2,732 -1,359.2%   
CASH FLOW
From Operations Rs m16,660-1,304 -1,277.8%  
From Investments Rs m-32,82512,697 -258.5%  
From Financial Activity Rs m7,441-301 -2,476.3%  
Net Cashflow Rs m-8,72411,093 -78.6%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 51.8 0.4%  
Indian inst/Mut Fund % 11.3 18.2 62.1%  
FIIs % 31.9 1.0 3,190.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 29.1 34.7%  
Shareholders   98,259 28,591 343.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 18, 2019 12:27 PM

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS